Patients with diabetes undergoing revascularization for lower extremity artery disease (LEAD) have longer diabetes duration and higher prevalence of advanced complications than those with coronary artery disease (CAD), independent of glycemic control.
The prevalence ratios for proliferative retinopathy, loss of protective sensation, and dialysis-dependent renal failure are significantly elevated in LEAD compared to CAD patients.
Glycemic control strategies, such as insulin-sensitizing therapy, may influence development of peripheral neuropathy but overall HbA1c levels at revascularization do not differ significantly between LEAD and CAD groups.
Understanding differential diabetes burden across vascular territories underscores the need for tailored management approaches and preventive strategies in vascular diabetic complications.
